Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration-Reference-Cited by-同舟云学术

Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration

Published:2024-09-05 Issue:11 Volume:73 Page:
ISSN:1432-0851
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Lu Yunxin,Jin Yin,Liu Furong,Wang Zixian,Zhou Wen,Zhang Yang,Bai Bing,Wang Yun,Wang Zhiqiang,Nie Man,Luo Huiyan,Wei Xiaoli,Liang Chuqiao,Guo Guifang,Qiu Miaozhen,Chen Jianwen,Liu Yu,Li Shengping,Li Yuhong,Wang Fenghua,Wang Feng,Chi Peidong,Zhang Dongsheng

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00262-024-03796-1.pdf

Reference40 articles.

1. Banales JM, Marin JJG, Lamarca A et al (2020) Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17:557–588. https://doi.org/10.1038/s41575-020-0310-z

2. Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX (2021) Biliary tract cancer. Lancet 397:428–444. https://doi.org/10.1016/S0140-6736(21)00153-7

3. Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73:198–222. https://doi.org/10.3322/caac.21759

4. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281. https://doi.org/10.1056/NEJMoa0908721

5. Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol Off J Eur Soc Med Oncol 30:1950–1958. https://doi.org/10.1093/annonc/mdz402